HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on ALX Oncology Holdings (NASDAQ:ALXO) and maintained a price target of $25.
June 10, 2024 | 10:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on ALX Oncology Holdings and maintained a price target of $25, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $25 price target by a reputable analyst firm like HC Wainwright & Co. suggests strong confidence in ALX Oncology Holdings' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100